

REFERENCES

=====

- Alcocer- Varela J and Alarcon-Segovia D: Longitudinal study on the production of and cellular response to interleukin-2 in patients with systemic lupus erythematosus. *Rheumatol Int*; 15: 57-63., 1995.
- Algers CE., Hopper J., Brenstein M. and Biava C.G.: Late development of systemic lupus erythematosus in patients with glomerular "fingerprint" deposits. *Ann. Intern. Med.*, 100: 66, 1984.
- Allison AC: Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. *Transplant Proc* 26: 3205-3210, 1994.
- Appel GB: Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. *Am. J. Med.* 83: 877, 1987.
- Appel GB., Pirani C.L. and D'Agati V.: Renal vascular complications of systemic lupus erythematosus. *J. Am. Soc. Nephrol.*, 4: 1499, 1994.
- Appel GB. and Valeri M.D.: The course and treatment of lupus nephritis. *Ann. Rev. Med.*, 45: 525-537, 1994.
- Arnett FC.: The Genetic Basis of lupus Erythematosus. In D.J. Wallace and B.H. Hahn (eds.), *Dubois' Lupus Erythematosus* (4th ed.) Philadelphia : Lea and Febiger, P., 13-36, 1993.
- Atkinson JP.: Genetic susceptibility and Class III complement Genes. In R.G. Lahita (ed.), *systemic Lupus Erythematosus* (2nd ed.), New York: Churchill Livingstone, P. 87-102, 1992.
- Atta MS., Powell RJ., Hopkinson ND. and Todd I.: Human anti-fibronectin antibodies in systemic lupus erythematosus. Occurrence and antigenic specificity. *Clin. Exp. Immunol.*, P. 6-20, 1994.

REFERENCES

=====

- Alcocer- Varela J and Alarcon-Segovia D: Longitudinal study on the production of and cellular response to interleukin-2 in patients with systemic lupus erythematosus. *Rheumatol Int*; 15: 57-63., 1995.
- Algers CE., Hopper J., Brenstein M. and Biava C.G.: Late development of systemic lupus erythematosus in patients with glomerular "fingerprint" deposits. *Ann. Intern. Med.*, 100: 66, 1984.
- Allison AC: Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. *Transplant Proc* 26: 3205-3210, 1994.
- Appel GB: Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. *Am. J. Med.* 83: 877, 1987.
- Appel GB., Pirani C.L. and D'Agati V.: Renal vascular complications of systemic lupus erythematosus. *J. Am. Soc. Nephrol.*, 4: 1499, 1994.
- Appel GB. and Valeri M.D.: The course and treatment of lupus nephritis. *Ann. Rev. Med.*, 45: 525-537, 1994.
- Arnett FC.: The Genetic Basis of lupus Erythematosus. In D.J. Wallace and B.H. Hahn (eds.), *Dubois' Lupus Erythematosus* (4th ed.) Philadelphia : Lea and Febiger, P., 13-36, 1993.
- Atkinson JP.: Genetic susceptibility and Class III complement Genes. In R.G. Lahita (ed.), *systemic Lupus Erythematosus* (2nd ed.), New York: Churchill Livingstone, P. 87-102, 1992.
- Atta MS., Powell R.J., Hopkinson ND. and Todd I.: Human anti-fibronectin antibodies in systemic lupus erythematosus. Occurrence and antigenic specificity. *Clin. Exp. Immunol.*, P. 6-20, 1994.

Austin HAIII, Muenz L.R., Joyce K.M., Antonouych, T.T., Kullick, M.E., Klippel, J.H., Decker, J.L. and Balow, J.E.: Prognostic factors in lupus nephritis: contribution of renal histologic data. *Am. J. Med.*, 75: 382-391, 1983.

Austin HAIII, Muenz L.R., Joyce K.M., Antonouych, T.A. and Balow, J.E.: Diffuse proliferative lupus nephritis; Identification of specific pathologic features affecting renal outcome. *Kidney. Int.*, 25: 689-695, 1984.

Austin HA., Brd, Klippel, J.H., Balow, J.E., Le Riche NGH, Steinberg A.D., Plotz, P.H. and Decker, J.L.: Therapy of lupus nephritis controlled trial of prednisone and cytotoxic drugs. *N. Eng. J. Med.*, 314: 614-619, 1986.

Austin HA.: NIH conference. Membranous nephropathy. *Am. Intern. Med.*, 116: 627, 1992.

Austin HAIII, Boumpas DT., Vaughn EM and Balow, JE.: Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data,. *Kidney. Int.*, 45: 544-550, 1994.

Austin HA, Vaughn EM and Boumpas DT: Lupus membranous nephropathy: Controlled trial of prednisone, pulse cyclophosphamide, and cyclosporine (abstract). *J Am Soc Nephrol.* 1328: A8411, 1997

Axelord L., Glucocorticoids. In W.N. Kelley, E.D., Harris, S., Ruddy and C.B., Sledge GB: *Textbook of Rheumatology* (4 th ed.), Philadelphia: Saunders, PP. 779-796, 1992.

Bagely CM, Bostick FW and DeVita VT: Clinical pharmacology of cyclophosphamide, *Cancer Research* 33: 226-233, 1973.

Baldwin DS., Lowenstein J., Rothfield N.F., Gallo G.R and McCluskey R.T.: The clinical causes of the proliferative and membranous form of lupus nephritis. *Ann. Intern. Med.*, 73: 929, 1970.

Balow J.: Lupus nephritis (NIH Conference). *Ann. Intern. Med.*, 106: 79, 1987.

Balow JE, and Austin HALL: Lupus nephritis. In Massy, S.G., Glasscock, R.H. (eds): Textbook of Nephrology, 2nd ed. Williams & Wilkins. Baltimore, PP 787-796, 1991-1992.

Bancroft JD and Stevens, A.: Theory and practice of histological Techniques., (2 nd ed.) Churchill Living stone., 1982.

Bansal VK and Beto JA: Treatment of lupus nephritis: A meta-analysis of clinical trials. Am J kidney Dis 29: 193-199, 1997.

Beckman SYNCHRON CX4/5 Chemistry Information Manual, 015-248053 (1991).

Berden JH: Lupus nephritis. Kidney. Int. 25: 538, 1997.

Bernstein KA., Valeri R.D. and Lefkowitz J.B.: glomerular binding activity in MRL lpr serum of antibodies that bind to a DNA/histone/type IV collagen complex. J.Immunol. 154: 2424, 1995.

Boumpas DT., Berez S., Klippel J.H. and Balow JE.: Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann. Intern. Med., 112: 647-677, 1990.

Boumpas DT: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet, 340: 741, 1992.

Boumpas DT., et al: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Intern. Med., 119: 366, 1993.

Boumpas DT., Austin, H.A., Epstein B.J., Balow J.E., Klippel J.H. and Lockshin M.D.: Systemic lupus erythematosus: Emerging concepts part 2, Ann. Intern. Med., 123: 42-53, 1995.

Boumpas DT., Austin H.A. 3rd, Epstein B.J.; Balow J.E., Klippel J.H. and Lockshin, M.D.: Systemic lupus erythematosus: emerging concepts. part I: Renal neuropsychiatric, cardiovascular, pulmonary and hematologic disease. Ann. Intern. Med., 122: 940-50, 1995.

Boumpas DT and Balow JE: Outcome criteria for lupus nephritis trials: A critical overview. *Lupus* 7: 622-629, 1998.

Bramwell V., Rouesse J and Steward W: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival. A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *Journal of Clinical Oncology* 12: 1137-1149, 1994.

Cameron JS.: Disease of the month, lupus nephritis. *J. Am. Soc. Nephrol.* 10: 1046-1069, 1999.

Cameron JS: Lupus nephritis in children. *Adv. nephrol.* 22: 59-117, 1993.

Carr SF, Papp E, Wu JC and Natsumeda Y: Characterization of human type I and type II IMP dehydrogenase. *J Biol Chem* 268: 27286-27290, 1993.

Cheigh JS and stenzel KH. End-stage renal disease in systemic lupus erythematosus. *Am.J. Kidney Dis.* 21:2, 1993.

Churg J, Bernstein J and Glasscock RJ: *Renal Disease*, Tokyo, Ikagu-Shoin, pp 151-179, 1995.

Ciruelo E., DE LA Cruz J, Lopez I and Gomez-Reino JJ: Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. *Arthritis Rheum* 12: 2028-2034, 1996.

Cohen AS., Reynolds, W.E and Franklin, E.C: Preliminary criteria for the classification of systemic lupus erythematosus. *Bull Rheum. Dis.* 21: 643,1971.

Cohen MC S. Cytokine function. A study in biologic diversity. *Am J Clin Pathol* : 105:589-98, 1996.

Cohen PL., and Eisenberg, R.A: Single gene models of systemic autoimmunity and lymphoproliferative disease. *Annu. Rev. Immunol.* 9: 243, 1991.

- Colvin M and Hilton J. Pharmacology of cyclophosphamide and metabolites. *Cancer Treat Rep.* 65 Suppl 3:89-95, 1981.
- Davis JC Jr, Austin, H III, Boumpas, D: A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. *Arthritis Rheum.* 41: 335, 1998.
- Davis JC., Manzi S., Yarboro C., Rairie J., McInnes I., Averbelyi D., Sinicropi D., Hale VG., Ballow J., Austin H., Boumpas DT and Kippel JH.: Recombinant human DNase-1 (th DNase) in patients with lupus nephritis, 8 (1): 68-76, 1999.
- Deapen D : A revised estimate of twin concordance in systemic lupus erythematosus. *Arthritis. Rheum.*, 35: 311, 1992.
- Decker JL., Steinberg AD., Reinersten JL., Plotz PH., Balow JE. and Klippel JH.: Systemic lupus erythematosus: Evolving concepts. *Ann. Int. Med.*, 91: 587-604, 1979.
- Dollery C., Boobis A., Rawins M., Thomas S and Wilkins M., (eds): *Therapeutic Drugs* (2 nd ed.), London : Churchill Livingstone PP 349: 354, 1999.
- Donadio JV and Glasscock RJ: Immunosuppressive drug therapy in lupus nephritis. *Am J Kidney Dis* 21: 239-250, 1993.
- Dooley MA., Cosia FG., Nachman PH., Falkenhain ME., Hogan SL., Falk RJ and Herbert LA., : Mycophenolate Mofetil therapy in Lupus Nephritis: Clinical observation. *Jam Soc of Nephrology.* 10: 833-844, 1999.
- Dostal C., Tesar V., Rychlik I., Zabka J., Vencovsky J., Bartunkova J., Stejskalova A and Tegzova D.: Effect of 1 year cyclosporine-A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. *Lupus.*, 7: 29-36, 1998.
- Drake CG. and Kotzin BL.: Genetic and immunological mechanisms in the pathogenesis of systemic lupus erythematosus. *Curr. Opin. Immunol.*: 4: 733, 1992.

- Drake CG: Genetic analysis of the NZB contribution to lupus-like autoimmune disease in (NZB x NZW) F₁ mice Proc. Natl. Acad. Sci. U.S.A., 91: 4062, 1994.
- Drake CG: Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner. J. Immunol., 154: 2441, 1995.
- Egorin MJ, Kaplan RS, Saloman M: Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide. Clinical Pharmacology and Therapeutics 32: 122-128, 1982.
- Elkon KB., Bonfa E. and Brot N.: Antiribosomal antibodies in systemic lupus erythematosus. Rheum. Dis. Clin. North. Am., 18: 377, 1992.
- Erb KJ, Rueger B, von Brevern M, Ryffel B, Schimpl A and Rivett K. Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice. J Exp Med; 185:329-339., 1997.
- Esdaile J.M., Levinton C and Federgreen W: The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: A study of 87 patients and review of the literature. Q. J., Med., 72: 779, 1989.
- Esdaile JM., Federgreen W, Quintal H: Predictors of one year outcome in lupus nephritis: The importance of renal biopsy. Q. J. Med., 81: 907-918, 1991.
- Esdaile JM., Joseph L., MacKenize T., Kashgrain M. and Hayslett JP.: The pathogenesis and prognosis of lupus nephritis : Information from repeat renal biopsy: Sem. Arthritis. Rheum., 23: 135, 1993.
- Eugui EM, Almquist S, Muller CD and Allison AC: Lymphocyte selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scan J Immunol 33: 161-173, 1991.
- Fauci AS., Haynes BF., Katz P and Wolff SM. Wegeners Granulomatosis; prospective clinical and therapeutic experience with 85 patients for 21 years. Annals of Internal Medicine 98:85, 1983.

- Feehally J., Beatic TJ and Brenchley PEC: Modulation of cellular immune function by cyclophosphamide in children with minimal-change nephropathy. *New England journal of Medicine* 310: 415-424, 1984.
- Fernandez JA: Recurrence of lupus nephritis in a renal allograft with histologic transformation of the lesion. *Transplantation.*, 50: 1056, 1990.
- Feutren G., Querin S., Tron F., Noel LH., Chatenoud L., Lesavre P. and Bach, JF.: The effects of cyclosporine in patients with systemic lupus. *Transplant. Proc.*, 18: 643-644, 1988.
- Finck BK., Linsley PS. and Wofsy D.: Treatment of murine lupus with CTLA41g. *Science*, 265: 1225, 1994.
- Fritzler MJ. and Rubin RL.: Drug-Induced Lupus. In D.J. Wallace and B.H. Hahn (eds.), *Dubois' lupus Erythematosus* (4th ed.). Philadelphia: Lea and Febiger, PP. 442-453, 1993.
- Fujimuro T, Hirose S., Jiag Y., Kodera S., Ohumuro H., Zhang D., Hamamo Y., Ishida H., Furukawa S and Shirai T.: Dissection of the effects of tumor necrosis factor-alpha and class II gene polymorphisms within the MHC on urine systemic lupus erythematosus. *Int Immunol* 10 (10): 1467-72, 1998.
- Gao CL., Li BA., Chen CZ., Yu Y.T., Yuan P. and Song, J.C.: Clinical trials of immunoadsorbent in systemic lupus erythematosus therapy. *Art. Organs.*, 19: 468-469, 1995.
- GISNEL (Gruppo Italiano Per Lo Studio Della Neprre Lupica): Lupus nephritis: Prognostic factors and probability of maintaining life-supporting renal function 10 years after diagnosis. *Am. J. Kidney. Dis.*, 19: 473-479, 1992.
- Glasscock RJ., Cohen AH. and Adler SG.: Secondary glomerular disease, in *The Kidney* (5th ed), edited by Brenner B.M., Philadelphia, W.B., saunders, pp 1489-1516, 1996.
- Golbus J and McCune WJ.: Lupus nephritis. Classification, prognosis, immunopathogenesis and treatment. *Rheum. Dis. Clin. North. Am.*, 20: 213-242, 1994.

- Gordon C, Richardson K and Bacon P: Elevated soluble adhesion molecules in SLE: relationship to disease activity. *Lupus*. 4 [Suppl 2]: 110, 1995.
- Hadidi AFA., Coulter CEA and Idle JR.: Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. *cancer Research* 48; 5167-5171, 1988.
- Hagiwara E, Gourley MF, Lee S, Klinman DM. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10 interferon gamma-secreting cells in the peripheral blood. *Arthritis Rheum*; 39: 379-385, 1996.
- Hahan BH. and Tsao BP.: Antibodies to DNA. In D.J. Wallace and B.H. Hahn (eds.), *Dubois' lupus Erythematosus* (4th ed.). Philadelphia: Lea and Febiger, PP. 195-201, 1993.
- Hall PD., Leshner BA and Hall RK Adjuvant therapy of node-negative breast cancer. *Annals of Pharmacotherapy* 29: 289-298, 1995.
- Handwerger BS, Rus V, da Silva L and via CS. The role of cytokines in the immunopathogenesis of lupus. *Springer Semin Immunopathol*; 16: 153-180., 1994.
- Hanly JG., Hong C., Zayed E., Jones JV and Jones E.: Immunomodulating effects of synchronized plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. *Lupus*, 4: 457-463, 1995.
- Hayes FA, Thompson EI and Mcyer W H: Therapy for localized Ewing's sarcoma of bone. *Journal of Clinical oncology* 7: 208-213, 1989.
- Hayslett JP and Kashgarian M.: Nephropathy of systemic erythematosus: Scherir Text. *Book of Nephrology*, P. 2255, 1994.
- Hellmann OB., Petri M and Wurring-O'Keefe Q.: Fatal infections in systemic lupus erythematosus: The role of opportunistic organisms. *Medicine*, 66: 341-348, 1987.

- Herron LR, et al., selection of the T. cell receptor repertoire in lpr mice. *J. Immunol.* 151: 3450, 1994.
- Hilliquin P, Borderie D and Fradelizi D: Interleukin-6 soluble receptor (sIL-6R) serum concentrations in systemic lupus erythematosus (SLE). *Lupus*; 4 [Suppl 2]: 25, 1995.
- Hochberg MC.: Epidemiology of systemic lupus erythematosus, in Dubois' *Systemic Lupus Erythematosus* (4th ed.), edited by Wallace, D.J., Hahn, B.H., Philadelphia: Lea and Febiger, PP. 49-57, 1992.
- Howard M. et al.: T cell derived cytokines and their receptors. In *Fundamental Immunology*; 3rd ed. Paul WE (editor). Raven Press Ltd, 1993.
- Imai H., Koclama T., Yauclo Y and Nakomoto A.B.: Miuro inverse relationship between serum cholinesterase activity and the administration of cyclophosphamide: an index of cyclophosphamide. *Nephrol. Dial. Transplant.*, 49 : 1240-9, 1994.
- Ioannidis JPA, Boki KA, Katsorida ME, Drosos AA, Boletis JN and Moutsopoulos MH: Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide, kidney. *Int*; 57: 258-284, 2000.
- Jacob CO and Hwang F. Definition of microsatellite size variants for TNFa and Hsp 70 in autoimmune nonautoimmune mouse strains. *Immunogenetics*; 36: 182-188, 1995.
- Juma FD, Rogers HJ and Trounce JR: The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nitroimidazole mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. *British Journal of Clinical Pharmacology* 10:327-335, 1980.
- Juma FD: Effect of liver failure on the pharmacokinetic of cyclophosphamide. *European Journal of Clinical Pharmacology* 26: 591-593, 1984.

- Kahl LE. and Atkinson JP.: Autoimmune aspects of complement deficiency. Clin. Aspects. Autoimmunity., 2 : 8, 1988.
- Kain R. et al.: A novel class of autoantigens of anti-neutrophils cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: The lysosomal membrane glycoprotein hamp-2 in neutrophils granulocytes and a related membrane protein in glomerular endothelial cells. J. Exp. Med., 181 : 585, 1995.
- Kalechman Y., Gafter U., Albeck M and Sredni B.: Suppression of interleukin 10 by the immunomodulator AS101 inhibits development of autoantibodies and glomerulonephritis in systemic lupus erythematosus (abstract). J Am Soc Nephrol. 8: 538A, 1997.
- Kant KS., Pollak VW and Weiss MA: Glomerular thrombosis in systemic lupus erythematosus: Prevalence and significance. Medicine, 60 : 71, 1981.
- Kashgarian M.: Lupus nephritis: Lessons from the Path. Lab. Kidney Int., 45 : 928-938, 1994.
- Kimblirly RP.: Treatment: Corticosteroids and anti-inflammatory drugs. Rheum. Dis. Clin. North Am., 14 : 203-221, 1988.
- Kippel JH.: Systemic lupus erythematosus: Treatment-related complication superimposed on chronic disease. J.A.M.A., 263 : 1812-1815, 1990.
- Kishimoto T., Taga T and Akira S. Cytokine signal transduction. Cell; 76: 253-62., 1994.
- Koffler D., Agenillo V., Carr I. and Kunkel H.G.: Variable patterns of immunoglobulin and complement deposition in the kidneys of patients with systemic lupus erythematosus. Am. J. Pathol., 56 : 305, 1969.
- Kotzin BL. and O'Dell JR.: Systemic Lupus Erythematosus. In M.M. Frank, K.F. Austen, N.H. Claman and E.R. Unanue (eds.), Samter's Immunologic Diseases. (5th ed.), Boston: Little Brown, Pp. 667-697, 1994.

- Levine LA and Richie JP.: Urological complications of cyclophosphamide. J. Urol., 141 : 1063-1069, 1989.
- Levitt M., Warr D and Yelle J: Ondansetron compared with dexamethon and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexat and flurouracil. New England of medicin 338: 1081, 1993.
- Lewis EJ., Kawala K and Schwartz MM.: Histological features that correlate with the prognosis of patients with lupus nephritis. Am. J. Kidney. Dis., 10 : 192-197, 1987.
- Lewis FJ., Hunsicker LG., Lan SP., Rhode RD and Lachin JM.: A controlled trial of plasmapheresis therapy in severe lupus nephritis. The lupus Nephritis Collaborative Study Group. N. Engl. J. med., 326 : 1373-1379, 1992.
- Lin CY., Hsu HC and Chiang H.: Improvement of histological and immunological changes in steroid and immunosuppressive drug-resistant lupus nephritis by high dose 1gG. Nephron. 53: 303, 1989.
- MacLennan I C M., Kelly K., Crockson RA., Cooper EH., Cuzick J. Chapman C., Results of the MRC myelomatosis trials for patients entered since 1980. Haematological Oncology 6: 145-158, 1988.
- Magil AB., Ballon HS and Rae A.: Focal proliferative lupus nephritis: A clinicopathologic study using the WHO classification. Am. J. Med., 72 : 620. 1982.
- Mark FG, Austin HA., Scott D., Yarboro CH., Ellen MV., Muir J and Boumpas DT., Klipple JH., Balow JE., steinberge AD., Methley L. pridinsolone and cyclophosphamide, Alan or in combination, in patients with lupus nephritis, Annals of Internal Medicine 125: 549-557, 1996.
- Maroni G., La-Marchesine U., Bandi G., Nador F., Vigano E., Marconi M., Lotto A and Panticelli C.: Cardiologic abnormalities in patients with long-term lupus nephritis. Clin. Nephrol., 43 : 20-8, 1995.

- Martelli M., Vignetti M. and Zinzani PL.: High dose chemotherapy followed by autogous bone marrow transplantation versus dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. *Journal of Clinical Oncology* 14: 534-512. 1996.
- Mattes WB. Hartely JA. and Kohn KW., DNA sequence selectivity of guanine-N7 alkylation by nitrogen mustards. *Nucleic Acids Research* 14: 2971-2987, 1986.
- Mattes WB., Hartley JA. and Kohn KV.: DNA sequence selectivity of guanine N7 alkylation by nitrogen mustards. *Nucleic Acids Research* 14: 2961-2987, 1986.
- McCarty GA., Harley JB. and Reichlin M.: A distinctive autoantibody profile in black female patients with lupus nephritis. *Arthritis. Rheum.*, 11 : 1560, 1993.
- McCune W., Golbus J. and Zeldes W: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. *N. Engl. J. Med.*, 318 : 1423, 1988.
- McCune WJ.: Immunosuppressive drug therapy. *Curr. Opin. Rheum.*, 8 : 183 : 187, 1996.
- McGuire WP., Hoskins WJ. and Brady MSF: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *New England Journal of Medicine* 334: 1-6., 1996.
- MCLAughlin JR. et al.: Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. *Arthritis. Rheum.*, 37 : 559, 1994.
- Melvin M., Schwartz MM., Shu-Ping Lan, Jaybernstein, Gray S., Hili Kethholicy, Edmund J. and Lewis and The Lupus Nephritis Collaborative Study group: Role of pathology indices in the management of severe lupus glomerulonephritis. *Kidney International* 42 : 734-748, 1992.

- Merkel F., Netzer KO., Gross O., Marx M. and Wnber: Therapeutic options for critically ill patients suffering from progressive lupus nephritis or Goodpasture's syndrome. *Kidney Int. Vol.*, 53, Suppl. PP. s-31-s-38, 1998.
- Mills JA.: Systemic lupus erythematosus. *N. Engl. J. Med.*, 330 : 1871-1879, 1996.
- Mohan C. et al.: Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. *J. Immunol.*, 154 : 1470, 1995.
- Mohan C. et al.: Nucleosome: A major immunogen for pathogenic autoantibody-inducing T cells of lupus. *J. Exp. Med.*, 17 : 1367, 1993.
- Monestier M. and Kotzin BL.: Antibodies to histones in systemic lupus erythematosus and drug-induced syndromes. *Rheum. Dis. Clin. North. Am.*, 18 : 415, 1992.
- Morioka T., Woitas R., Fujigak T., et al.: Histone mediates glomerular deposition of small size DNA anti-DNA complex. *Kidney Int.*, 45 L 991, 1994.
- Morris RE., Hoyt EG. and Murphy MP.: Mycophenolic acid morpholinoethylester (RS-61433) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T-and B-cell purine synthesis. *Transplant Proc* 22: 1659-1662, 1990.
- Muehrcke R., Kark R., Pirani C. and Pollak V.: Lupus nephritis: A clinical and pathologic study based on renal biopsies. *medicine*, 36 : 1, 1967.
- Nossent HC., Henzer-Log SC., Vroom TM., Berden JMH. and Swaak TJG.: Contribution of renal biopsy data in predicting outcome in lupus nephritis. *Arthritis. Rheum.*, 33 : 970-97, 1990-1991.
- Oberle GP., He:mchen U. and Stahl RA.: Lupus nephritis. *Internist. Berl.*, 36 : 236-44, 1995.

- Oppenheim JJ. and Rescetti FW.: Cytokines Medical Immunology. ninth ed. Butler J (editor). A simson & schuster company, P: 146-168., 1997.
- Park M., D'Agati A., Appel G. and Pirani CL.: Tubulointerstitial disease in lupus-nephritis: Relationship to immune deposits, interstitial inflammation glomerular changes, renal function, and prognosis. Nephron., 44 : 309, 1986.
- Pistiner M., Wallace DJ. and Nessim S.: Lupus erythematosus in the 1980s: A survey of 570 patients. Semin. Arthritis. Rheum., 21 : 55-64, 1991.
- Pollak VE., Pirani CL. and Kark RM.: Effect of large does of prednisone on the renal lesions and lifespan of patients with lupus erythematosus. J. Lab. Clin. Med., 57 : 495, 1961.
- Ponticelli C.: Treatment of lupus nephritis: The advantages of a flexible approach. Nephrol Dial Transplant 12: 2057-2059, 1997.
- Radhakrishnan J., Szabo S. and S'Agah V.: Lupus membranous Nephropathy: Course and prognosis in 50 patients. (abstract) J. Am. Soc. Nephrol., 4 : 284, 1993.
- Radic MZ. : Residues that mediate DNA binding of autoimmune antibodies. J. Immunol., 150 : 4966, 1993.
- Raz E., Dudler J., Lotz M., Baird SM., Berry CC., Eisenberg RA. and Carson DA.: Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus, 4 : 286-292, 1995.
- Reichlin M. and Harley JB.: Antinuclear Antibodies: An Overview. In DJ. Wallace, and BH. Hahn (eds.), Dubois Lupus Erythematosus (4th ed.), Philadelphia: Lea and Febiger, Pp. 188-194, 1993.
- Rothfield N.: Lupus nephritis. In Schur P (ed): Clinical Management of Systemic Lupus Erythematosus. Grune & Stratton. New York, 1983.

- Roubey RAS.: Lupus anticoagulant activity of auto-immune antiphospholipid antibodies is dependent upon B2-glycoprotein I. J. Clin. Invest., 90 : 1100, 1992.
- Rus V., Svetic A., Nguyen P., Gauce WC. and Via CS. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8⁺T cells. J Immunol; 155: 2396-2406., 1995.
- Sander O. and Rou R.: Therapy of refractory chronic poly arthrititis with tumor necrosis factor alpha receptor fusion protein (TNR 55-IgG1). Long term follow-up of 80 personal cases. 57 (5): 307-11, 1998.
- Sany J.: Intravenous immunoglobulin therapy for rheumatic disease. Curr. Opin. Rheum., 6 : 305-310, 1994.
- Schmahl D. and Habs M. Carcinogenic action of low dose cyclophosphamide given orally to Sprague-Dawley rats in a lifetime experiment. international journal of Cancer 23: 706-712, 1979.
- Schroeder JO., Zeuner RA., Euler HH. and Löffler H.: High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study. J. rheum., 23 : 71-75, 1996.
- Schumacher M. and Bastert G, H.: Randomized 2x2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive cancer patients. German Breast Cancer Study Group. Journal of Clinical Oncology 12: 2086-2093, 1994.
- Schwartz MM., Lan SP. and Bernstein J.: Role of pathology indices in the management of severe lupus glomerulonephritis. Kidney Int., 42 : 743, 1992.
- Schwartz MM., Lan SP. and Bernstein J.: Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Am. J. Kidney. Dis., 21 : 374, 1993.

- Schwartz MM., Kawala K. and Roberts JL.: Clinical and pathological features of membranous glomerulonephritis of systemic lupus erythematosus. *Am. J. Nephrol.*, 4 : 301, 1984.
- Schwartz MM.: The role of renal biopsy in the management of lupus nephritis. *Semin. Nephrol.*, 5 : 255, 1985.
- Seleznick MJ. and Fries JF.: Variables associated with decreased survival in systemic lupus erythematosus. *Semin. Arthritis. Rheum.*, 21 : 73-80, 1991.
- Shafford EZ. and Rogers DW., Prictchard J.: Advanced neuroblastoma, improved response rate using multiagent regimen (OEC) including sequential cisplatin and VM 26. *Journal Clinical Oncology* 2: 42-747, 1984.
- Sharp GC., and Singesen BH.: Mixed Connective Tissue Disease. In D.J. McCarty (ed.), *Arthritis and Allied Conditions: A Textbook of Rheumatology* (11th ed.), Philadelphia: Lea and Febiger, Pp. 1980-1091, 1989.
- Sladek NE. : Powis G. and Prough RA: Metabolism and action of cancer drugs. *Talor and Francis*, London, P46-90, 1987.
- Smith IE., Evans BD. and Harland SJ.: High dose cyclophosphamide (7 g.m²) with or without autologous bone marrow rescue after conventional chemotherapy in the treatment of patients with small cell lung cancer. *Cancer Treatment Reviews* 10 (suppl. A): 79-81, 1983.
- Sobh M., Moustafa F., Foda MA, Hafez A., Bakr MA. and Ghoneim MA.: Lupus nephritis: Clinicopathologic correlation and prognostic indicators. *AF J. Nephrol*, 1: 32-39; 1997.
- Souhami RL, finn G. and Gregory ~W M: High dose cyclophosphamide in small cell carcinoma of the lung. *Journal of Clinical Oncology* 3: 958-963, 1985.
- Spronk PE, ter Borg EJ, Huitema MG, Limburg PC and Kallenberg CG: Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study. *Ann Rheum Dis*; 53: 235-239., 1994.

- Stafford FJ., Fleisher TA., Lee- G., Brown M., Strand V., Austin HA., 3rd, Balow, J.W. and Klippel, J.H.: A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus. *J. Rheumatol*, 21 : 2068-70, 1994.
- Steinberg AD. and Gourley M.: Cyclophosphamide in lupus nephritis. (editorial) *J Rheumatol*; 22: 1812-1814, 1995.
- Steinberg AD. and Steinberg SC.: Long term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. *Arth Rheum*, 34 : 945-959, 1991.
- Stoan RP., Schwartz MM., Korbel BM. and Borok RZ.: Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. *Lupus Nephritis Collaborative Study Group. J. Am. Soc. Nephrol.*, 7 : 299-305, 1996.
- Sturefelt G., Eskilsson J., Noived O., Truedsson L. and Valind S.: Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population. *Medicine (Baltimore)* 71 : 216-223, 1992.
- Tam LS., Li EK., Leung CB. et al. Long-term treatment of lupus nephritis with cyclosporin A. *Q J Med* 91: 537, 1998.
- Tan EM.: Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology. *Advances Immunol.*, 44. : 93-151, 1980.
- Tan EM., Cohen AS. and Fried JF: The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis. Rheum.*, 25 : 1271, 1982.
- Tateno S: Study of lupus nephritis: Its classification and the significance of subendothelial deposits. *Q.J. Med.*, 52 : 311, 1983.
- Termaat RM., Assmann KJM. and Van Son JPHF. et al.: Antigen-specificity of antibodies bound to glomeruli of mice with systemic lupus erythematosus-like syndromes. *Lab. Invest.*, 68 : 164-172, 1993.

- Tesar V, Masek Z, Rychlik I, Merta M, Bartumkova J, Stejskalova A, Zabka J, Janatkoval I, Dostal C and Becvar R: Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. *Nephrol Dial Transpl*; 13: 1662-1667, 1998.
- Tesar V., Jirsa Mgr., Masek Z., Bortunkova J., Stejskalova A., Dostal C., Zabka J., Chabova V. and Rysava R.: Soluble cytokinin receptors in renal vasculitis and lupus nephritis. 4; 137 (9): 271-5, 1998.
- Tietz NW.: Ph. D., Edited by, "Textbook of Clinical Chemistry", W.B. Saunders Co., Philadelphia (1986).
- Tsao BP.: Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. *J. Immunol.*, 149 : 350, 1992.
- Tsokos GC.: Overview of Cellular Immune Function in Systemic Lupus Erythematosus. In R.G., Lahita (ed.), *Systemic Lupus Erythematosus* (2nd ed.), New York: Churchill Livingstone, pp. 15-20, 1993.
- Valeri A., Radhakrishnan J., Eshs D., D'Agah V., Kopelman R., Pernis A., Elis R., Pirani C. and Appel GB.: Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: A prospective five-year study. *Clin. Nephrol.*, 42 : 71-78, 1994.
- Vassalli P. : The pathophysiology of tumour necrosis factor. *Annu Rev Immunol*; 10: 411-52, 1992.
- Wada T, Yokoyama H and Tomosugi N: Detection of urinary interleukin-8 in glomerular diseases. *Kidney Int*; 46: 455-460, 1994.
- Wallace DJ.: The clinical presentation of SLE, in Dubois's *Systemic Lupus Erythematosus* (4th ed), edited by Wallace DJ., Hahn BH., Philadelphia, Lea & Febiger, pp 317-321, 1992.
- Wang Y., Hu Q., Madri JA., Rollins SA., Chodera A. and Matis LA.: Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. *Proc. Natl. Acad. Sci. USA.*, 93 : 8563-8568, 1996.

Weidner N. and Lorentz WB.: Scanning electron microscopy of acellular glomerular and tubular basement membrane in lupus nephritis. Am. J. Clin. Pathol., 85 : 135, 1986.

Weinstein A., Bordwell B., Tibbetts C. and Rothfield NF., Antibodies to native DNA and serum complement (C3) levels: application to diagnosis and classification of systemic lupus erythematosus. Am J Med 74:206, 1983.

Wernick RM.: Reliability of histologic scoring for lupus nephritis: A community-based evaluation. Ann. Intern. Med., 119 : 805, 1993.

Wilson M. " Antinuclear Antibodies and Anticytoplasmic Antibodies in Lupus Erythematosus" in Dubois' Lupus Erythematosus, 3rd edition DJ Wallace and EL Dubois, ed (Lea and Febiger: Philadelphia) 227, 1987.

Winchester R.: Genetic Susceptibility to Systemic Lupus Erythematosus. In R.G. Lahita (ed.), Systemic Lupus Erythematosus (2nd ed.), New York: Churchill Livingstone, pp. 65-85, 1992.

Wofsy A.: Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. J. Immunol., 136 : 4554, 1985-1986.

Zoja C., Corna D. and Benedetti G.: Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. kidney Int; 53:726, 1998.